Sponsored by Aimmune Therapeutics.
Kirsten Beyer, MD
A. Wesley Burks, MD, FAAAAI
George Du Toit, MD, FAAAAI
Anna H. Nowak-Wegrzyn, MD, FAAAAI
Wayne Shreffler, MD, PhD
- Every day, more than 5 million people with peanut allergy in the US and Europe are at risk of severe reactions from accidental exposures to peanuts. Recent data indicate AR101, delivered through CODIT™, is an emerging treatment option for peanut allergy.
- This symposium will review the mechanisms of food allergy and desensitization; evaluate results and highlight key learnings from academic clinical trials in peanut oral immunotherapy (OIT); and provide safety and efficacy results from Aimmune’s phase 2 clinical trials of AR101.
- A subsequent faculty panel discussion will answer questions and provide clinicians with insights and perspectives on OIT.